A detailed history of Ubs Oconnor LLC transactions in Minerva Neurosciences, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 107,256 shares of NERV stock, worth $240,253. This represents 0.02% of its overall portfolio holdings.

Number of Shares
107,256
Holding current value
$240,253
% of portfolio
0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.55 - $3.4 $18,870 - $25,160
7,400 Added 7.41%
107,256 $286,000
Q2 2024

Aug 14, 2024

BUY
$2.33 - $3.65 $493 - $773
212 Added 0.21%
99,856 $318,000
Q1 2024

May 15, 2024

BUY
$2.5 - $12.47 $87,500 - $436,450
35,000 Added 54.14%
99,644 $257,000
Q4 2023

Feb 14, 2024

SELL
$3.96 - $7.85 $21,209 - $42,044
-5,356 Reduced 7.65%
64,644 $397,000
Q3 2023

Nov 14, 2023

BUY
$6.9 - $13.05 $483,000 - $913,500
70,000 New
70,000 $483,000

Others Institutions Holding NERV

About Minerva Neurosciences, Inc.


  • Ticker NERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,340,190
  • Market Cap $12M
  • Description
  • Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein ...
More about NERV
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.